HCAT Stock Forecast 2025-2026
Distance to HCAT Price Targets
HCAT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Health Catalyst (HCAT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HCAT and similar high-potential opportunities.
Latest HCAT Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, HCAT has a bullish consensus with a median price target of $8.00 (ranging from $4.00 to $16.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $3.84, the median forecast implies a 108.3% upside. This outlook is supported by 9 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sarah James at Cantor Fitzgerald, projecting a 316.7% upside. Conversely, the most conservative target is provided by Elizabeth Anderson at Evercore ISI Group, suggesting a 4.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCAT Analyst Ratings
HCAT Price Target Range
Latest HCAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| Apr 9, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Downgrade | $4.00 |
| Mar 6, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $5.00 |
| Feb 27, 2025 | Stifel | David Grossman | Hold | Maintains | $5.00 |
| Feb 27, 2025 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $6.00 |
| Feb 27, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Reiterates | $7.00 |
| Feb 11, 2025 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $8.00 |
| Jan 21, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $10.00 |
| Jan 21, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $10.00 |
| Jan 15, 2025 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $7.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Upgrade | $9.00 |
| Nov 26, 2024 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $12.00 |
| Nov 14, 2024 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $9.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.50 |
| Nov 7, 2024 | RBC Capital | Sean Dodge | Sector Perform | Maintains | $9.00 |
| Oct 8, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $10.00 |
| Oct 4, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $16.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $16.00 |
| Sep 4, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $13.00 |
Health Catalyst Inc. (HCAT) Competitors
The following stocks are similar to Health Catalyst based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Health Catalyst Inc. (HCAT) Financial Data
Health Catalyst Inc. has a market capitalization of $269.61M with a P/E ratio of -3.3x. The company generates $306.58M in trailing twelve-month revenue with a -22.7% profit margin.
Revenue growth is +6.0% quarter-over-quarter, while maintaining an operating margin of -18.6% and return on equity of -19.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Health Catalyst Inc. (HCAT) Business Model
About Health Catalyst Inc.
Provides data and analytics solutions for healthcare.
The company operates on a subscription-based model, offering its Data Operating System (DOS) platform to healthcare organizations. By aggregating and analyzing healthcare data, Health Catalyst enables providers to improve clinical and financial outcomes, thereby generating revenue through software licensing and support services.
Health Catalyst is a key player in the digital transformation of healthcare, focusing on big data solutions. Its services target multiple healthcare sectors, including hospitals and health systems, helping to reduce costs and enhance patient care through data-driven insights.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,500
CEO
Mr. Daniel D. Burton
Country
United States
IPO Year
2019
Website
www.healthcatalyst.comHealth Catalyst Inc. (HCAT) Latest News & Analysis
Health Catalyst, Inc. (Nasdaq: HCAT) will release Q1 2025 operating results on May 7, 2025, after market close, followed by a conference call at 5:00 pm ET.
Health Catalyst's upcoming Q1 2025 results and conference call may significantly influence its stock performance and investor sentiment, impacting market positions and valuations.
Health Catalyst (Nasdaq: HCAT) launched Ignite Spark™, a data and analytics solution aimed at community health systems and regional hospitals, addressing challenges like shrinking margins and policy uncertainty.
Health Catalyst's launch of Ignite Spark targets community health systems facing financial challenges, potentially boosting its market share and revenue amid industry pressures.
AI-driven healthcare companies, including Butterfly Network and Health Catalyst, are positioned to become significant players in the industry.
AI-driven healthcare firms like Butterfly Network and Health Catalyst may present significant growth opportunities, indicating potential high returns for investors focusing on innovative sectors.
Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook
25 days agoHealth Catalyst (HCAT) reports $307M in revenue and $26M in adjusted EBITDA for 2024, despite a 50% stock price drop. The company anticipates $335M revenue in 2025 and aims for improved margins.
HCAT's stock drop contrasts with its strong revenue and EBITDA growth, AI focus, margin improvements, and client expansion, suggesting potential undervaluation and future profitability for investors.
Recent activity in the options market indicates that investors should closely monitor Health Catalyst (HCAT) stock.
Options market activity can indicate investor sentiment and potential price movements for Health Catalyst (HCAT), signaling possible volatility or trading opportunities.
Health Catalyst, Inc. (Nasdaq: HCAT) repurchased approximately $5 million of its common stock between March 3 and March 10, 2025, as part of a $40 million buyback program approved in August 2022.
Share repurchases typically indicate management's confidence in the company's value, potentially signaling to investors a commitment to enhancing shareholder value.
Frequently Asked Questions About HCAT Stock
What is Health Catalyst Inc.'s (HCAT) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Health Catalyst Inc. (HCAT) has a median price target of $8.00. The highest price target is $16.00 and the lowest is $4.00.
Is HCAT stock a good investment in 2025?
According to current analyst ratings, HCAT has 9 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCAT stock?
Wall Street analysts predict HCAT stock could reach $8.00 in the next 12 months. This represents a 108.3% increase from the current price of $3.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Health Catalyst Inc.'s business model?
The company operates on a subscription-based model, offering its Data Operating System (DOS) platform to healthcare organizations. By aggregating and analyzing healthcare data, Health Catalyst enables providers to improve clinical and financial outcomes, thereby generating revenue through software licensing and support services.
What is the highest forecasted price for HCAT Health Catalyst Inc.?
The highest price target for HCAT is $16.00 from Sarah James at Cantor Fitzgerald, which represents a 316.7% increase from the current price of $3.84.
What is the lowest forecasted price for HCAT Health Catalyst Inc.?
The lowest price target for HCAT is $4.00 from Elizabeth Anderson at Evercore ISI Group, which represents a 4.2% increase from the current price of $3.84.
What is the overall HCAT consensus from analysts for Health Catalyst Inc.?
The overall analyst consensus for HCAT is bullish. Out of 20 Wall Street analysts, 9 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are HCAT stock price projections?
Stock price projections, including those for Health Catalyst Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.